ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia
- Author(s)
- Hourigan, CS; Dillon, R; Beugelink, L; Hwan Kim, DD; Othman, J; Valk, PJM; Gui, G; Ivey, A; Thiede, C; Levis, MJ; Dillon, LW; Wei, AH; Tiong, IS; Loo, S; Döhner, K; Arnhardt, I; Kowalik, A; Potter, N; Preudhomme, C; Duployez, N; Heuser, M;
- Details
- Publication Year 2026-08-13,Volume 148,Issue #7,Page 910-913
- Journal Title
- Blood
- Publication Type
- Guideline
- Abstract
- FLT3-internal tandem duplication measurable residual disease testing for patients in remission from acute myeloid leukemia is now recommended by the recently updated clinical standard-of-care guidelines. This companion technical note provides important laboratory and clinical recommendations regarding such testing.
- Publisher
- American Society of Hematology
- Keywords
- *fms-Like Tyrosine Kinase 3/genetics; Humans; *Leukemia, Myeloid, Acute/genetics/diagnosis; *Neoplasm, Residual/genetics/diagnosis; *Tandem Repeat Sequences; *High-Throughput Nucleotide Sequencing/methods
- Department(s)
- Haematology; Pathology
- Publisher's Version
- https://doi.org/10.1182/blood.2026033569
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-06-23 03:42:06
Last Modified: 2026-09-16 04:43:30